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Metformin is the first-line drug in the treatment of type 2
diabetes. In addition to its hypoglycemic effect, metformin has
an anti-inflammatory function, but the precise mechanism pro-
moting this activity remains unclear. Highmobility group box 1
(HMGB1) is an alarmin that is released from necrotic cells and
induces inflammatory responses by its cytokine-like activity and
is, therefore, a target of anti-inflammatory therapies. Here we
identified HMGB1 as a novel metformin-binding protein by
affinity purification using a biotinylated metformin analogue.
Metformin directly bound to the C-terminal acidic tail of
HMGB1. Both in vitro and in vivo, metformin inhibited inflam-
matory responses induced by full-length HMGB1 but not by
HMGB1 lacking the acidic tail. In an acetaminophen-induced
acute liver injurymodel in whichHMGB1 released from injured
cells exacerbates the initial injury, metformin effectively
reduced liver injury and had no additional inhibitory effects
when the extracellular HMGB1 was blocked by anti-HMGB1-
neutralizing antibody. In summary, we report for the first time
that metformin suppresses inflammation by inhibiting the
extracellular activity ofHMGB1. BecauseHMGB1 plays amajor
role in inflammation, our results suggest possible new ways to
manage HMGB1-induced inflammation.
Metformin, a biguanide derivative, is a hypoglycemic drug in
widespread clinical use for type 2 diabetes treatment (1, 2).
Metformin lowers blood glucose mainly by inhibiting gluco-
neogenesis in liver (1, 2). Inside cells, metformin suppresses
ATP production by inhibiting mitochondrial complex 1 and
glycerophosphate dehydrogenase to increase the AMP/ATP
ratio that subsequently activates AMP-activated protein kinase
(AMPK)4 (1, 2). It is proposed that the hypoglycemic effect of
metformin is due to an increased AMP/ATP ratio that sup-
presses glucagon signaling (3) and inhibits hepatic gluconeo-
genic enzymes in AMPK-dependent and -independent man-
ners (1, 2).
In addition to its hypoglycemic effect,metformin has an anti-
inflammatory effect. In vitro, metformin suppresses lipopoly-
saccharide (LPS)-induced inflammatory responses in macro-
phages (4, 5) and endothelial cells (6). In vivo, metformin
reduces serum levels of tumornecrosis factor (TNF) in high-
fat diet-induced obese mice (7). At present, metformin is con-
sidered to suppress inflammation partly through improvement
of blood glucose levels and more directly through AMPK-
dependent and -independent inhibition of nuclear factor B
(NFB) pathway (8).
In diabetic patients, metformin has been demonstrated to
prevent various diseases such as cardiovascular diseases (9) and
cancer (10, 11). Furthermore, metformin has hepatoprotective
effects; it improves non-alcoholic steatohepatitis in humans
(12) and prevents alcohol- and drug-induced liver injury in
mice (13–16). Because inflammation is a major contributor to
these diseases (17), metformin could protect these diseases at
least through its anti-inflammatory function (4–6, 18, 19).
However, its precise anti-inflammatory mechanism remains
unclear.
Endogenous molecules released from damaged cells, termed
alarmins, enhance inflammation that subsequently exacerbates
the initial injury (20, 21). High mobility group box 1 (HMGB1)
is amultifunctional protein acting as a DNA chaperon involved
in the regulation of gene expression and also as an alarmin that
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extracellularly induces inflammation by stimulating variable
receptors such as Toll-like receptor 4 (TLR4) and the receptor
for advanced glycation end products (RAGE) (22–25). Clini-
cally, serum HMGB1 levels are increased in patients with vari-
ous inflammation-related diseases including traumatic injury,
acute liver failure, myocardial infarction, and sepsis (26). Fur-
thermore, inhibition of HMGB1 has been demonstrated to
ameliorate various diseases in animal models as administration
of anti-HMGB1 antibody inhibited traumatic brain injury (27)
and increased survival rate of LPS-induced shock (28). These
data provoke interest in HMGB1 as an attractive target for the
development of new therapeutic agents for inflammation-re-
lated diseases (29–31).
In this study we identified HMGB1 as a novel metformin-
binding protein and demonstrated that metformin inhibited
cytokine activity of HMGB1 in vitro and in vivo. This is the first
report of an extracellular function of metformin that regulates
inflammation induced by HMGB1.
Results
Identification of HMGB1 as ametformin-binding protein
To identify unknown targets of metformin, we performed
affinity chromatography by using a biotinylated compound
containingmetformin-like biguanide structure immobilized on
avidin beads (hereafter called metformin beads) (Fig. 1A) and
rat liver cytosol. As shown in Fig. 1B, we specifically detected an
25-kDa protein in the eluate of the metformin beads but not
in that of the control beads. Mass spectrometry analysis
revealed the protein was HMGB1. HMGB1 in the cytosolic
fraction of HepG2 hepatocellular carcinoma cells was also
bound to the metformin beads, and their association was com-
Figure 1. Identification of HMGB1 as a novel metformin-binding protein. A, structure of metformin (upper) and the biotinylated compound containing
metformin-like biguanide structure (lower) used for the affinity chromatography. B, affinity purification was performed from rat liver cytosol with the met-
formin beads and the control biotin beads. Bead eluates were analyzed by SDS-PAGE followed by silver staining. Mass spectrometry analysis revealed the
25-kDaprotein indicated by the arrowwasHMGB1.C, HMGB1 in cytosolic fraction of HepG2 cellswas pulled downwith themetformin beads in the presence
of indicatedconcentrationsofmetformin.D, recombinantHMGB1waspulleddownwith themetforminbeadsor control beads in thepresenceof the indicated
concentrations ofmetformin, phenformin, putrescine, or 6-aminohexanoic acid.Data shownare representativeof three independent experimentswith similar
results.
Metformin Inhibits HMGB1 Proinflammatory Cytokine Activity
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petitively inhibited by metformin in a concentration-depen-
dent manner (Fig. 1C). We prepared purified recombinant
HMGB1 using the baculovirus expression system. The recom-
binant HMGB1 bound to the metformin beads (Fig. 1D),
indicating that their association was direct. The binding of
recombinant HMGB1 to the metformin beads was concen-
tration-dependently inhibited in the presence of metformin
and also phenformin, another biguanide derivative, but not other
amide-containing compounds such as putrescine and 6-amino-
hexanoic acid (Fig. 1D). Thus, the interaction of HMGB1 was
specific to the biguanide structure.
Metformin bound to the C-terminal acidic tail of HMGB1
HMGB1 contains three major functional domains: A box
domain at the N terminus, B box domain in the middle that
possesses cytokine activity, and a C-terminal acidic tail domain
consisting of 30 acidic amino acids (32, 33) (Fig. 2A). To deter-
mine the binding site of metformin, we prepared recombinant
proteins of full-length HMGB1, A box, B box, an acidic tail,
acidic tail-deleted HMGB1 (HMGB1-AT) and A box-deleted
HMGB1 (HMGB1-A box) (Fig. 2A). Then we performed a
pulldown assay with the metformin beads. As shown in Fig. 2B,
HMGB1 mutants containing the acidic tail (full-length
HMGB1, acidic tail and HMGB1-A box) clearly bound to the
metformin beads, whereas mutants lacking the acidic tail
(A box, B box, and HMGB1-AT) did not. The association
between recombinant full-length HMGB1 and the met-
formin beads was concentration-dependently inhibited in
the presence of the acidic tail but not HMGB1-AT (Fig.
2C). These results indicated that metformin bound to the
acidic tail of HMGB1.
Metformin inhibited p38 phosphorylation induced by HMGB1
but not that induced by HMGB1-AT inmacrophages
HMGB1 induces proinflammatory cytokine production such
as TNF through stimulating receptors such as TLR4 and acti-
vation of p38, c-Jun N-terminal kinase (JNK), and NFB path-
way inside cells (32, 33). In the present study we focused on p38
phosphorylation as a cellular signaling response induced by
HMGB1. Full-length HMGB1 or HMGB1-AT at 1 g/ml
(40 nM) clearly induced p38 phosphorylation in RAW264.7
macrophage cells after incubation at 37 °C for 1 h (Fig. 3, A and
B). This phosphorylation was strongly inhibited by a TLR4
inhibitor, TAK-242 (supplemental Fig. 1), suggesting that
HMGB1 activates p38 mainly through TLR4 in RAW264.7
cells. Preincubation with metformin inhibited HMGB1-in-
duced p38 phosphorylation (Fig. 3,A and B). It is noted that the
inhibition was preincubation time-dependent (Fig. 3, A and B).
In the same experiment, AMPK phosphorylation was not sig-
nificantly increased by metformin (Fig. 3, A and C), probably
due to short incubation periods. These results indicated that
metformin inhibited the HMGB1-TLR4 pathway indepen-
dently of AMPK activation.
Metformin concentration-dependently inhibited p38 phos-
phorylation induced by full-length HMGB1 but not that
induced byHMGB1-AT (Fig. 4,A and B). Similar results were
obtained with mouse peritoneal macrophages (Fig. 5, A and B).
As expected, metformin did not affect p38 phosphorylation
induced by LPS, a direct TLR4 agonist (Figs. 4, A, and B, and 5,
A and B). Again, in these conditions metformin did not alter
AMPK phosphorylation levels (Figs. 4, A, and C, and 5, A and
C). Thus, metformin specifically inhibited HMGB1-induced
p38 phosphorylation in RAW264.7 cells as well as mouse peri-
toneal macrophages through direct interaction with the acidic
tail of HMGB1.
Metformin did not alter the redox states ormolecular weight
of HMGB1
HMGB1 contains three cysteine residues at positions 23, 45,
and 106, and their redox states determine its extracellular cyto-
kine activity (34, 35). Once released from cells, fully reduced
HMGB1 is gradually oxidized to become disulfide HMGB1
with a disulfide bond between Cys-23 and Cys-45 in the A box
domain (33). Disulfide HMGB1 has proinflammatory cytokine
activity, whereas fully-reduced HMGB1 does not (34, 35). To
clarify themolecularmechanismbywhichmetformin inhibited
HMGB1, we examined the redox states of HMGB1 by gel elec-
trophoresis (35). The recombinant HMGB1 used in our exper-
iments was in the disulfide form, as -mercaptoethanol
(2-ME)-treated fully-reduced HMGB1 clearly migrated slower
(Fig. 6A) as described previously (35). After the incubation of
HMGB1 with metformin at 4 °C for 1 h or 24 h, metformin did
not alter the migration velocity of HMGB1, indicating that
HMGB1was not reduced bymetformin (Fig. 6A). The data also
demonstrated that HMGB1 was not degraded by incubation
with metformin (Fig. 6A). We then examined whether met-
formin bound to HMGB1 with a covalent linkage such as an
amide bond. Mass spectrometry analysis revealed that the
molecular weight of HMGB1 was not altered after incubation
Figure 2. Metformin bound to HMGB1 through its acidic tail. A, domain
structure of HMGB1 and its mutants used in this study. B, purified His-tagged
HMGB1 and its mutants were pulled down with the metformin beads and
detected by immunoblottingwith anti-His antibody. I, input (30%); C, control
beads; M, metformin beads. C, full-length HMGB1 was pulled down with the
metforminbeads in thepresenceof the indicatedconcentrationsof theacidic
tail or HMGB1-AT. Data shown are representative of three independent
experiments with similar results.
Metformin Inhibits HMGB1 Proinflammatory Cytokine Activity
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with metformin at 4 °C for 24 h (Fig. 6B). Thus, we could not
detect changes in the redox state or in the molecular weight of
HMGB1 after incubation with metformin.
Metformin inhibited TNF elevation induced by HMGB1 but
not that induced by HMGB1-AT inmice
We then examined the effect ofmetformin onTNF produc-
tion induced by HMGB1 in vivo (32, 33). As shown in Fig. 7A,
intraperitoneal administration of HMGB1 or HMGB1-AT
markedly increased serum TNF levels after 2 h. Simultaneous
administration ofmetformin inhibitedHMGB1-induced eleva-
tion of TNF levels by40% but did not inhibit HMGB1-AT
induced elevation. When HMGB1 was preincubated with met-
formin at 4 °C for 24 h, the increase of TNF levels induced by
HMGB1 was more strongly inhibited, as was the case with in
vitro experiments shown in Fig. 3. It is noted thatmetformin did
not inhibit the HMGB1-AT-induced increase of TNF levels
even after preincubation at 4 °C for 24 h. Thus, metformin
inhibited HMGB1-induced elevation of TNF in vivo through
interaction with the acidic tail of HMGB1. As expected, met-
formin did not inhibit LPS-induced TNF elevation (Fig. 7B),
suggesting that the inhibition of TNF elevation is specifically
due to the binding of metformin with HMGB1.
Metformin did not exert further inhibition of acetaminophen-
induced liver injury inmice under blockade of HMGB1 cytokine
activity
Acetaminophen overdose is well known to cause drug-in-
duced liver injury where HMGB1 has been demonstrated to be
an essential alarmin in the aggravation of the liver damage
through enhancement of inflammation (36). In contrast, met-
formin has been demonstrated to reduce acetaminophen-in-
duced liver injury (16). In the final sets of experiments, we
examinedwhethermetformin can inhibit endogenousHMGB1
in the acetaminophen intoxication. Metformin as well as
anti-HMGB1-neutralizing monoclonal antibody efficiently
suppressed the levels of alanine transaminase (ALT), a specific
marker of hepatocellular damage, by 70% (Fig. 8A), and
reduced the damaged area in liver parenchyma to a similar
extent (Fig. 8B). Under the condition that extracellularHMGB1
was blocked by the anti-HMGB1-neutralizing antibody,
metformin did not additionally ameliorate acetaminophen-
induced liver injury and vice versa (Fig. 8). It has been demon-
strated that metformin ameliorates the acetaminophen-
induced liver injury by inducing gene expression of a JNK
inhibiting factor, Gadd45 (16). Similar to the previous report
(16), metformin showed a tendency to induce Gadd45 ex-
pression while administration of anti-HMGB1 antibody also
induced it (supplemental Fig. 2). Importantly, again, this effect
of anti-HMGB1 antibody was not enhanced by metformin
(supplemental Fig. 2). Then, we examined whether HMGB1
targets hepatocytes using human hepatocyte cell lines. As
shown in supplemental Fig. 3, recombinant HMGB1 did not
induce cell injury in HepG2 hepatocytes. Although acetamino-
phen induced injury in the cells, the addition of recombinant
HMGB1 did not increase the number of injured cells, and anti-
HMGB1-neutralizing antibody did not decrease it. Further-
more, HMGB1 did not induce p38 phosphorylation in HepG2
and HuH7 hepatocytes but efficiently induced it in RAW264.7
macrophage cells under the same conditions (supplemental Fig.
4). These results suggest that the main target of HMGB1 is not
Figure 3. Metformin inhibited HMGB1-induced p38 phosphorylation in
RAW264.7 cells in a preincubation time-dependent manner. RAW264.7
cells were stimulated with 1 g/ml HMGB1 in the absence or presence of 10
mM metformin at 37 °C for 1 h. HMGB1 was preincubated with metformin at
4 °C for the indicated periods before the addition to cells. Cell lysates were
subsequently analyzedby immunoblotting for phosphorylated and total p38
and phosphorylated and total AMPK. A, typical photos of immunoblots. Data
shown are representative of four independent experiments with similar
results. B and C, ratios of phosphorylated/total p38 (B) and phosphorylated/
total AMPK (C) were calculated from densitometry analysis. B and C, results
were analyzed as the percentage of control group (HMGB1 alone). Data are
presented as themean S.E. (n 4). **, p 0.01; ***, p 0.001 versus control
group.
Metformin Inhibits HMGB1 Proinflammatory Cytokine Activity
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hepatocytes but inflammatory cells as reported previously (36).
Thus, metformin ameliorated acetaminophen-induced liver
injury inmicemost likely through interactingwith extracellular
HMGB1 and inhibiting HMGB1 cytokine activity.
Discussion
Metformin has been demonstrated to possess an anti-inflam-
matory function besides its hypoglycemic effect (29–31). How-
ever, the precise mechanism of its anti-inflammatory effect
remains to be clarified. In this study we identified HMGB1 as a
novel metformin-binding protein (Fig. 1). We demonstrated
thatmetformin directly bound toHMGB1 through its C-termi-
nal acidic tail (AT) (Fig. 2) and that metformin inhibited p38
phosphorylation in macrophage cells (Figs. 4 and 5) and eleva-
tion of serum TNF levels in mice (Fig. 7A) induced by full-
length HMGB1 but not that induced by HMGB1-AT. Fur-
thermore, we showed that metformin most likely inhibited
endogenous HMGB1 acting as an alarmin in the acetamino-
phen-induced liver injury mice (Fig. 8).
Metformin exerts anti-inflammatory function viaAMPK-de-
pendent and -independent mechanisms (8). Although it has
been shown that metformin indirectly and slowly suppresses
Figure 4.Metformin inhibited p38 phosphorylation induced byHMGB1 but not that induced byHMGB1-AT in RAW264.7 cells. RAW264.7 cells were
incubated with 1g/ml full-length HMGB1, HMGB1-AT, or LPS in the absence or presence of indicated concentrations of metformin at 37 °C for 1 h. HMGB1
or LPS were preincubated without or with metformin at 4 °C for 24 h before the addition to cells. Cell lysates were then analyzed by immunoblotting for
phosphorylated and total p38 and for phosphorylated and total AMPK. A, typical photos of immunoblotting. Data shown are representative of four indepen-
dent experiments with similar results. B and C, ratios of phosphorylated/total p38 (B) and phosphorylated/total AMPK (C) were calculated from densitometry
analysis. B and C, results were analyzed as the percentage of control group (HMGB1 alone in left panels, HMGB1-AT alone in center panels, and LPS alone in
left panels). Data are presented as mean S.E. (n 4). ***; p 0.001 versus control group.
Metformin Inhibits HMGB1 Proinflammatory Cytokine Activity
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inflammation through activating AMPK (4, 5), the mechanism
of AMPK-independent anti-inflammatory effect is not clearly
elucidated. In contrast to studies that show longer exposure
(about 4–24 h) to metformin activates AMPK in cultured cells
(5, 37), metformin did not increase AMPK phosphorylation in
our study; this is most likely due to the shorter exposure time (1
h) (Figs. 3–5). In this condition, without activation of AMPK,
metformin inhibited HMGB1-induced p38 phosphorylation
(Figs. 3–5). Thus, we could demonstrate that metformin inhib-
ited the HMGB1-induced inflammatory response indepen-
dently of AMPK. This is the first identification of a target of
metformin that could explain AMPK-independent direct anti-
inflammatory mechanism.
HMGB1 is specifically associated with the biguanide struc-
ture as metformin and another biguanide derivative, phen-
formin, inhibited the association of HMGB1 with the met-
formin beads (Fig. 1, D and E). We showed that metformin
bound to the acidic tail of HMGB1 (Fig. 2B) but observed no
changes in redox state (Fig. 6A) ormolecular weight of HMGB1
(Fig. 6B) after incubation with metformin. Therefore, the
molecular mechanism of metformin in the inhibition of
HMGB1 cytokine activity remains elusive. The acidic tail of
HMGB1, to which metformin bound, is composed exclusively
of negatively charged amino acids in contrast to A box and B
box containing many positively charged amino acids (26). It has
been reported that the negatively charged acidic tail interacts with
AboxandBboxdomainsandregulates thewholeconformationof
HMGB1 (38, 39). Considering biguanide is a positively charged
polyamine (1, 2) (Fig. 1A),metforminmayassociatewith theacidic
tail throughelectrical interactionsandmay induceconformational
change of whole HMGB1. Because the effective anti-HMGB1-
neutralizing antibody used in this study also recognizes the acidic
tail of HMGB1 (40), the acidic tail could be a reasonable target for
the regulation of cytokine activity of HMGB1.
As shown in Fig. 7A, metformin strongly inhibited HMGB1-
induced elevation of TNF levels in mice. Similar to in vitro
experiments, metformin did not inhibit TNF elevation
induced by HMGB1-AT (Fig. 7A). These results indicate that
the inhibitory effect of metformin inmice was indeedmediated
by the direct interaction between metformin and the acidic tail
of HMGB1. Importantly, this anti-inflammatory effect was
observed without preincubation of HMGB1 and metformin,
suggesting that metformin could interact in vivo with HMGB1
to inhibit its cytokine activity. Thus, the anti-inflammatory
effect ofmetformin could bemediated by the inhibition of cyto-
kine activity of HMGB1 in vivo.
Metformin is known to protect liver against injury induced
by various drugs such as carbon tetrachloride (14), methotrex-
ate (15), and acetaminophen (16). It has been demonstrated
thatHMGB1 released fromnecrotic hepatocytes plays a critical
role in the acetaminophen-induced liver injury model by accel-
erating the primary injury (26) as the liver injury is drastically
reduced in hepatocyte-specific HMGB1 knock out mice (36) or
by administration of anti-HMGB1-neutralizing antibody (41).
We showed that both metformin and anti-HMGB1-neutraliz-
ing antibody reduced acetaminophen-induced liver injury to
the same extent and that simultaneous administration of
them exhibited no additional inhibition compared with anti-
HMGB1-neutralizing antibody alone (Fig. 8, supplemental Fig.
2). These results suggest that metformin acts in the same
pathway with anti-HMGB1-neutralizing antibody. Given that
metformin directly inhibitedHMGB1 cytokine activity as dem-
Figure 5. Metformin inhibited HMGB1-induced p38 phosphorylation in
mouse peritoneal macrophages. Mouse peritoneal macrophages from
Balb/cmicewere incubatedat 37 °C for 1hwith1g/ml full-lengthHMGB1or
1g/ml HMGB1-AT in the absence or presence of 3mMmetformin. HMGB1
or HMGB1-AT was preincubated without or with metformin at 4 °C for 24 h
before the addition to cells. Cell lysates were then analyzed by immunoblot-
ting for phosphorylated and total p38 and for phosphorylated and total
AMPK. A, typical photos of immunoblots. Data shown are representative of
four independent experiments with similar results. B and C, ratios of phos-
phorylated/total p38 (B) and phosphorylated/total AMPK (C) were calculated
from densitometry analysis. B and C, results were analyzed as the percentage
of control group (HMGB1 alone or HMGB1-AT alone). Data are presented as
mean S.E. (n 4). *, p 0.05 versus control group.
Metformin Inhibits HMGB1 Proinflammatory Cytokine Activity
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onstrated in this study, the target ofmetformin in this acetamin-
ophen-induced liver injurycouldbeendogenousHMGB1thatwas
released from damaged hepatocytes. In acetaminophen-induced
injury inculturedhepatocytes,neitherHMGB1noranti-HMGB1-
neutralizing antibody altered the number of injuredHepG2 hepa-
tocytes. In addition, p38 phosphorylation in HepG2 and HuH7
cells was not induced byHMGB1 or LPS. This could be due to the
low expression levels of TLR4 in these cells. Because it has been
reported that HMGB1 enhances acetaminophen-induced liver
injury by activating neutrophils (36), these results suggest that
metformin reduces acetaminophen-induced liver injury via inhi-
bition of HMGB1-induced inflammatory responses.
Metformin has been demonstrated to prevent various dis-
eases such as cardiovascular diseases (9) and cancer (10, 11) in
diabetic patients, compared with other anti-diabetic drugs
under similar glycemic control levels. Interestingly, serum
HMGB1 levels are shown to be significantly elevated in these
diseases (42, 43). Because administration of anti-HMGB1-neu-
tralizing antibody reduces atherosclerosis in mice (44) and a
peptide that antagonizes B box cytokine activity prevents can-
cer progression (45–47), blockade of HMGB1 could be an
effective therapeutic strategy for treating these diseases. Our
results suggest that inhibition of HMGB1 could contribute to
the protective effect of metformin against cardiovascular dis-
eases and cancer in diabetic patients.
In clinical settings, the maximal approved daily dose of met-
formin is 2.5 g (35 mg/kg body weight) and the achievable
plasma concentrations of metformin are 40–70 M in the por-
tal vein and 10–40 M in the systemic circulation (48). Similar
to previous studies (4, 5, 13, 16), we used 0.1–10mMmetformin
for cellular experiments and 350 mg/kg for in vivo experiments
with mice. These concentrations are apparently higher than
those observed in human clinical usage. It would be important
to evaluate the contribution of metformin to the inhibition of
HMGB1 cytokine activity in patients treated with metformin.
However, because our results showed that a high dose of met-
formin had an anti-inflammatory effect in vitro and in vivo,
supra-therapeutic doses of metformin could potentially be use-
ful as an anti-inflammatory drug for diseases where HMGB1
plays a critical role.
Figure 6. Metformin did not change the redox states or molecular weight of HMGB1. A, HMGB1 was incubated at 4 °C in the absence or presence of 100
mMmetformin for the indicated time periods and analyzed by SDS-PAGEwithout or with -mercaptoethanol (2-ME) treatment at 95 °C for 5min. HMGB1was
detectedby immunoblottingwith anti-HMGB1antibody. It is noted that disulfide and fully-reducedHMGB1 canbe separatedbymobility in SDS-PAGEwithout
2-ME treatment. Bands in themarker (M) lane indicated 30, 40, and 50 kDa from the bottom. B, mass spectrometry analysis of HMGB1 incubatedwithout (upper
diagram) or with 100 mM metformin (lower diagram) at 4 °C for 24 h.
Metformin Inhibits HMGB1 Proinflammatory Cytokine Activity
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We here focused on the effect of metformin on the cytokine
activity of HMGB1 that is extracellularly released. Because met-
formin is known to alter gene expression profiles (5, 16), met-
formin could affect the chromatin regulatory function of intracel-
lular HMGB1 in cells where metformin is absorbed and
concentrated. This issue remains to be clarified in future studies.
In summary, we have reported here for the first time an
extracellular function of metformin that directly interacts with
HMGB1 and inhibits its cytokine activity. Because HMGB1
plays amajor role in the pathology of inflammation-related dis-
eases, our results would provide a deeper understanding of the
molecular action of metformin and a new perspective on the
development of drugs targeting HMGB1.
Experimental procedures
Materials and antibodies
Metformin (1,1-dimethylbiguanide hydrochloride), phen-
formin (N-[2-phenylethyl]imidodicarbonimidic diamide
monohydrochloride), and biotin were purchased from Sigma.
Anti-HMGB1, anti-phosphorylated p38, anti-total p38, anti-
phosphorylated AMPK, and anti-total AMPK antibodies
were purchased from Cell Signaling Technology (Danvers,
MA). Anti-His antibody was from Sigma. Horseradish peroxi-
dase-conjugated anti-mouse IgG and anti-rabbit IgG secondary
antibodies were from Jackson ImmunoResearch (West Grove,
PA). Anti-HMGB1 neutralizingmonoclonal antibody and con-
trol anti-keyhole limpet hemocyanin (KLH) antibody (IgG2a
isotype control) were generated as described (40). LPSwas from
InvivoGen (San Diego, CA). TAK-242 was from EMD chemi-
cals (San Diego, CA). Other chemicals were purchased from
Sigma or Wako (Osaka, Japan).
Identification ofmetformin-binding protein
All procedures were performed at 4 °C unless otherwise
specified. Liver cytosolwas prepared by homogenizing rat livers
in buffer A (50 mM HEPES/KOH, pH 7.4, 78 mM KCl, 4 mM
MgCl2, 2 mM EGTA, 0.2 mM CaCl2, 1 mM dithiothreitol) con-
taining protease inhibitors using a glass-Teflon homogenizer.
Samples were then centrifuged at 120,000  g for 1 h. The
supernatant was used as a rat liver cytosol. For the preparation
Figure 7.Metformin inhibitedHMGB1-induced TNF elevation in vivo. A
and B, Balb/cmice were intraperitoneally administered full-length HMGB1 or
HMGB1-AT at 1mg/kg (A) or LPS at 0.1mg/kg (B) in the absence or presence
of 300 mg/kg metformin. As a control, PBS vehicle was injected. In some
experiments HMGB1, HMGB1-AT, or LPS was preincubated with metformin
at 4 °C for 24 h before injection. Serum TNF levels were measured by ELISA
2 h after peritoneal administration. Data are presented as the mean  S.E.
(n 7). **, p 0.01; ***, p 0.001 versus HMGB1 alone.
Figure8.Metformindidnotexhibit further inhibitionwhenextracellular
function of HMGB1 was blocked by anti-HMGB1-neutralizing antibody
in the acetaminophen-induced liver injurymodel mice. Balb/c mice were
intraperitoneally administered 400 mg/kg acetaminophen without or with
350mg/kgmetformin. Control antibody or anti-HMGB1 antibody at 5mg/kg
was simultaneously administered intravenously. A, serum ALT levels were
measured 5 h after acetaminophen administration. Data are presented as the
mean S.E. (n 6–8). *, p 0.05. NS, no significant difference. B, represen-
tative data of H&E staining in liver tissues 5 h after acetaminophen adminis-
tration. Scale bar, 500 m.
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of the affinity column, biotinylated compound containing met-
formin-like biguanide structure (Fig. 1A) or biotin as a control
was immobilized on NeutrAvidin-agarose resin (Thermo Fis-
cher Scientific,Waltham,MA). After the beads were incubated
with the rat liver cytosol for 1 h, theywerewashedwith Buffer A
4 times, and the bead-associated proteins were eluted with
Buffer A containing 100mMmetformin at 30 °C for 10min. The
eluates of themetformin beads and the control beads were ana-
lyzed by sodium dodecyl sulfate-polyacrylamide gel electro-
phoresis (SDS-PAGE) followed by silver staining. An25-kDa
band observed specifically in the eluate of the metformin beads
was determined by mass spectrometry analysis.
Preparation of recombinant proteins
Human HMGB1 gene was cloned by polymerase chain reac-
tion (PCR) amplification from human bone marrowMarathon
cDNA (Clontech, Mountain View, CA). The PCR product was
ligated into a pFastBacHTb vector (Invitrogen) at BamHI and
XhoI sites. Mutants of HMGB1, including A box, B box, acidic
tail-deleted HMGB1 (HMGB1-AT), and A box-deleted
HMGB1 (HMGB1-A box) (Fig. 2A), were also cloned in a
similar manner. His-tagged full-length HMGB1 and its
mutants were produced in Sf9 insect cells by the baculovirus
expression system. The acidic tail sequence was cloned into a
pRSETA vector (Invitrogen), and theHis-tagged acidic tail was
produced using Escherichia coli strain BL21 (DE3). All His-
tagged proteins were then purified on nickel nitrilotriacetic
acid (NTA)-agarose beads (Qiagen, Hilden, Germany) accord-
ing to themanufacturer’s instructions. Full-lengthHMGB1 and
HMGB1-AT were used after cleavage of their His tags by
tobacco etch virus protease (Turbo TEV protease; Accelagen,
San Diego, CA) in all the experiments except for Figs. 1 and 2.
All proteins were subsequently purified by gel filtration with a
Superdex 200 Increase column (GE Healthcare) equilibrated
with phosphate-buffered saline (PBS).
Pulldown experiments to examine the interaction between
HMGB1 andmetformin
Purified recombinant HMGB1, its mutants, or the cytosolic
fraction of HepG2 hepatocellular carcinoma cells was incu-
bated at 4 °C for 1 hwith themetformin beads or control biotin-
immobilized beads prepared as described above in the presence
of various concentrations of the competitive agents: met-
formin, phenformin, putrescine, 6-aminohexanoic acid (Fig. 1,
C and D) as well as recombinant acidic tail or HMGB1-AT
(Fig. 2C). After the beads were washed four times, bead-associ-
ated proteins were eluted with the SDS-containing Laemmli
buffer without or with -mercaptoethanol (2-ME). They
were analyzed by SDS-PAGE or by Tricine-SDS-PAGE for
Fig. 2B followed by immunoblotting with anti-HMGB1 or
anti-His antibodies and visualized by chemiluminescence re-
agent (Immunostar Zeta; Wako).
Preparation of cultured cells
RAW264.7 mousemacrophage cells (RIKEN BRCCell Bank,
Ibaraki, Japan) were cultured in RPMI1640 supplemented with
10% fetal bovine serum, 100 units/ml penicillin, and 100 g/ml
streptomycin (Nacalai Tesque, Kyoto, Japan) in 5% CO2 at
37 °C.HepG2 andHuH7 cells were cultured inDMEMmedium
supplementedwith 10% fetal bovine 100 units/ml penicillin and
100 g/ml streptomycin in 5% CO2 at 37 °C. Mouse peritoneal
macrophages were obtained by the intraperitoneal injection of
2ml of sterile 2% thioglycollate solution (w/v) (BD Biosciences)
into male Balb/c mice (8 weeks, 18–23 g; Japan SLC Inc.,
Hamamatsu, Japan) as described previously (49). After 4 days,
peritoneal cells were collected in PBS by peritoneal lavage, and
cells attached on the bottom of culture dishes after 24 h of
culture were used as mouse peritoneal macrophages.
In vitro p38 phosphorylation assay
RAW264.7 cells, mouse peritoneal macrophages, HepG2
cells, and HuH7 cells were seeded at 3  105 cells/well in
12-well culture plate (Sumitomo Bakelite Co., Ltd., Tokyo,
Japan) and cultured for 24 h. Sub-confluent cells prepared as
described above were then incubated with 1 g/ml or the indi-
cated amounts of HMGB1, 1 g/ml HMGB1-AT, or 1 g/ml
LPS and incubated at 37 °C for 1 h. They were added to cells
after preincubation without or with various concentrations of
metformin at 4 °C for the indicated periods in some experi-
ments. TAK-242 was added 30 min before adding HMGB1 at 1
g/ml. After incubation, cells were washed with ice-cold PBS
and lysed by the addition of 250 l of buffer A containing 1%
Triton X-100, 10 mM -glycerophosphate, 10 mM sodium fluo-
ride, 1 mM vanadate, and protease inhibitor mixture. After cen-
trifugation at 20,000 g for 10min, supernatants of cell lysates
were analyzed by SDS-PAGE followed by immunoblotting with
anti-phosphorylated p38, anti-total p38, anti-phosphorylated
AMPK, or anti-total AMPK antibodies. Band intensities were
quantified using Image J.
Mass spectrometry analysis
Samples were desalted using Zip Tip C4, mixed with matrix
solution (10 mg/ml sinapinic acid in 0.3% TFA/70% acetonitrile),
and analyzed on an AB SCIEX TOF/TOFTM5800 System
(SCIEX, Framingham,MA) to determine themolecular weights.
In vivo evaluation of HMGB1-induced TNF levels
HMGB1 or HMGB1-AT at 1 mg/kg or LPS at 0.1 mg/kg
was intraperitoneally administered without or with 300 mg/kg
metformin to male Balb/c mice (8 weeks old, 18–23 g; Japan
SLC) after fasting for 24 h. In some experiments, HMGB1,
HMGB1-AT, or LPS was preincubated with metformin at
4 °C for 24 h before administration. Blood was collected after
2 h, and serum TNF concentrations were measured by an
ELISA (TNF mouse ELISA kit; R&D systems, Minneapolis,
MN) according to the manufacturer’s instructions.
Evaluation of acetaminophen-induced liver injury in amouse
model
Before acetaminophen administration, Balb/c mice (8 weeks
old, 18–23 g) were fasted for 16–18 h. Acetaminophen at 400
mg/kg was intraperitoneally administered to mice without or
with 350mg/kgmetformin. Anti-KLHmonoclonal antibody or
anti-HMGB1-neutralizing antibody at 5 mg/kg was intrave-
nously administered to mice immediately after acetaminophen
administration. Blood was collected 5 h after administration,
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and serum ALT concentrations were measured. At the same
time, liver was fixed in 10% neutral buffered formalin (Wako),
embedded in paraffin, cut into 5-m-thick sections, and
stained with hematoxylin and eosin (H&E). The sections were
observed under a microscope (BZ-9000, Keyence, Osaka,
Japan). Total RNA was extracted from mouse livers using an
RNeasymini kit (Qiagen). Reverse transcriptionwas performed
using ReveTra ACE qPCR RT Master Mix (TOYOBO, Osaka,
Japan). Quantitative RT-PCR was performed using SYBR pre-
mix Ex TaqII (Takara, Shiga, Japan) with the CFX96 qPCR
detection system (Bio-Rad). Changes of expression level of each
gene were analyzed by the Ct method using mouse -actin
gene as an endogenous control. The primers for mouse
Gadd45 were 5-ATTGACATCGTCCGGGTATCAG-3
(forward) and 5-TTGGTTATTGCCTCTGCTCTCTT-3
(reverse). In acetaminophen-induced cell injury assay using
cultured hepatocytes, HepG2 cells were seeded at 2 104/well
in 8-well cover glass chambers (IWAKI, Sizuoka, Japan) and
cultured for 20 h. Then the medium was changed to 400 l of
the medium containing 0 mM or 20 mM acetaminophen with
1.5 g/ml anti-KLH monoclonal antibody, 1.5 g/ml anti-
HMGB1-neutralizing antibody, or 1 g/ml HMGB1 and incu-
bated at 37 °C for 24 h. After staining with Hoechst 33342
(DOJINDO, Kumamoto, Japan) at 1 g/ml and propidium
iodide at 0.5 g/ml, the number of live and dead cells in ran-
domly selected fields was visually measured using a fluorescent
microscopy (BZ-9000, Keyence, Osaka, Japan).
Statistical analysis
Data shown are expressed as the means  S.E. Two-way
analysis of variance analysis was performed. Each comparison
was performed usingDunnett’s test or Student’s t test. A p value
of0.05 was considered significant.
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Supplemental Figure 1. TLR4 inhibitor reduced HMGB1-induced p38 
phosphorylation in RAW 264.7 cells
RAW264.7 cells were treated with 1 μg/ml TLR4 inhibitor TAK-242 at 37℃ for 
30min and then stimulated with 1 μg/ml HMGB1 at 37℃ for 1 h. Cell lysates were 
subsequently analyzed by immunoblotting for phosphorylated and total p38. (A) 
Typical photos of immunoblots. Data shown are representative of four independent 
experiments with similar results. (B) Ratios of phosphorylated/total p38 were 
calculated from densitometry analysis. Results were analyzed as the percentage 
of control group (HMGB1 alone). Data are presented as mean ± SEM (n=4). ***; 
P < 0.001 vs. control group.
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Supplemental Figure 2. Metformin and anti-HMGB1 antibody induce change 
of gene expression in acetaminophen-induced liver injury model
Balb/c mice were intraperitoneally administered 400 mg/kg acetaminophen without 
or with 350 mg/kg metformin. Control antibody or anti-HMGB1 antibody at 5 mg/kg 
was simultaneously administered intravenously. Relative expression levels of 
Gadd45β after 5h in liver were measured. Data are presented as mean ± SEM 
(n=6-8). ***; P<0.01.
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Supplemental Figure. 3 HMGB1 had 
no effect on the acetaminophen-
induced injury of hepatocytes in vitro
HepG2 cells were incubated with 20 mM
acetaminophen, HMGB1 at 1 μg/ml, and 
anti-HMGB1 neutralizing antibody at 1.5 
μg/ml at 37℃ for 24 h. Then the cells 
were stained with Hoechst, cell 
permeable DNA dye (blue) and 
propidium iodide, cell impermeable DNA 
dye (red), the number of cells were 
visually counted. (A) The rate of injured 
cells (magenta) were calculated. Data 
are presented as mean ± SEM (n = 3). 
NS; not significant, ***; P < 0.001.
(B) Representative data of microscopy 
images. Scale bar; 200 μm.
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Supplemental Figure. 4: HMGB1 induced no inflammatory response in 
cultured hepatocytes
RAW264.7, HepG2, and Huh7 cells were incubated with 0-5 μg/ml of HMGB1 or 
0-1 μg/ml of LPS. Cell lysates were subsequently analyzed by immunoblotting for 
phosphorylated and total p38. (A) Typical photos of immunoblots. Data shown 
are representative of four independent experiments with similar results. (B) 
Ratios of phosphorylated/total p38 was calculated from densitometry analysis. 
Results were analyzed as the percentage of control group (no HMGB1 and LPS 
group in each cell line). Data are presented as mean ± SEM (n = 3). NS; not 
significant, *; P<0.05, and **; P < 0.01 vs. control group.
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